LINC01184 promotes hepatocellular carcinoma development via the miR-193a-3p/DCAF7 axis

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern, often developing in patients with chronic liver disease.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development and progression.
• Understanding the specific functions of lncRNAs like LINC01184 in HCC is crucial for identifying new therapeutic strategies.

Purpose of the Study:

• To investigate the role of LINC01184 in hepatocellular carcinoma (HCC) cell malignancy.
• To explore the impact of LINC01184 on xenograft tumor growth in HCC models.
• To elucidate the molecular mechanism by which LINC01184 influences HCC progression.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (RT-qPCR) to measure LINC01184 expression.
• Cellular assays (colony formation, Transwell) to assess proliferation, invasion, and migration.
• Luciferase reporter and RNA immunoprecipitation (RIP) assays to determine molecular interactions and in vivo xenograft models to evaluate tumorigenesis.

Main Results:

• LINC01184 expression was significantly elevated in HCC cells and promoted proliferation, migration, and invasion.
• LINC01184 functions as a competing endogenous RNA (ceRNA) by sponging miR-193a-3p, leading to increased DCAF7 expression.
• Overexpression of DCAF7 reversed the effects of LINC01184 depletion, and rescued tumor growth in vivo.

Conclusions:

• LINC01184 significantly promotes malignant phenotypes and tumor progression in HCC.
• The LINC01184/miR-193a-3p/DCAF7 axis is a key regulatory pathway in HCC.
• LINC01184 represents a potential therapeutic target for hepatocellular carcinoma.